Umbilical Cord Mesenchymal Stem Cells Transplantation in the Treatment of Chronic Obstructive Pulmonary Disease

• Status: Recruiting
• Trial end date: 2021-12-25
• Target enrollment: 0
• Participant gender: All

Summary

This trial is to investigate the safety and potential therapeutic efficacy of allogeneic administration of umbilical cord-derived MSCs (UC-MSCs) as a supplementary intervention in combination with standard COPD medication treatments in patients with moderate-to-severe COPD based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019 and Vietnam Ministry of Health's guidelines

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vinmec Research Institute of Stem Cell and Gene Technology

Criteria

Inclusion Criteria:

• Diagnosed with COPD with stage B, C, or D according to GOLD 2019.

• Age between 40-75 years old.

• Both genders.

Exclusion Criteria:

• Smoker or less than 6 months of smoking cessation time.

• Asthma and other pulmonary-related diseases and injuries (including lung tuberculosis, restrictive lung disease, idiopathic pulmonary fibrosis, or lung cancer).

• Acute and/or active infection.

• Cancer.

• Patients with complex cardiovascular diseases (including valvular heart disease, cardiomyopathy, arrhythmia, congenital heart disease, hypertrophy syndrome).

• Liver and kidney failure.

• Pregnancy.

• Patients with life expectancy less than 6 months due to concomitant illness.

• Under immunosuppressive treatment within 8 weeks of the first screening visit.

• Patient diagnosed diabetes with HbA1C>7%